Pascual, IsaacArzamendi, DabitCarrasco-Chinchilla, FernandoFernández-Vázquez, FelipeFreixa, XavierNombela-Franco, LuisAvanzas, PabloSerrador Frutos, Ana MaríaPan, ManuelCid Álvarez, Ana BelénHernández-Antolín, Rosa AnaAndraka Ikazuriaga, LeireCruz-González, IgnacioDíez Gil, José LuisAlcasena Juango, María SoledadBerenguer Jofresa, AlbertoAlonso-Briales, Juan HLi, Chi HionBenito González, TomásRegueiro, AnderArmijo, GermánLeón, VíctorAmat-Santos, Ignacio JRomero, MiguelTrillo Nouche, RamiroFernández-Golfín, CovadongaRuiz Gómez, LaraCampos-Arjona, RafaelMillán, XavierGarrote Coloma, CarmenSanchis, LauraJiménez-Quevedo, PilarMorís, CésarHernández-García, José MaríaSerra, AntonioPérez de Prado, ArmandoEstévez-Loureiro, Rodrigo2023-02-082023-02-082019-11-13http://hdl.handle.net/10668/14697Transcatheter mitral valve repair (TMVR) with MitraClip is a therapeutic option for high surgical risk patients with severe mitral regurgitation (MR). The main objective of this study was to analyze differences in outcomes in patients with severe MR according to the cause of MR. Observational, multicenter, and prospective study with consecutive patient inclusion. The primary endpoint was the combination of all-cause mortality and new readmissions due to heart failure after 1 year. We compared clinical and procedural characteristics and the event rate for each MR group. We performed a multivariate analysis to identify predictive variables for the primary endpoint. A total of 558 patients were included: 364 (65.2%) with functional etiology, 111 (19.9%) degenerative and 83 (14.9%) mixed. The mean age was 72.8±11.1 years and 70.3% of the sample were men. There were 95 (17%) events in the overall sample. No significant differences were found in the 3 groups in the number of primary outcome events: 11 (11.3%) in degenerative MR, 71 (21.3%) in functional MR, and 13 (18.1%) in mixed MR (P=.101). Independent predictors were functional class (P=.029), previous surgical revascularization (P=.031), EuroSCORE II (P=.003), diabetes mellitus (P=.037), and left ventricular ejection fraction (P=.015). This study confirms the safety and efficacy of TMVR with MitraClip irrespective of MR etiology in real-life data and shows the main factors related to prognosis during the first year of follow up.enAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/EtiologyEtiologíaInsuficiencia mitral graveMitraClipReparación de la válvula mitral transcatéterSevere mitral regurgitationTranscatheter mitral valve repairAgedAged, 80 and overCardiac CatheterizationFemaleHeart Valve Prosthesis ImplantationHumansMaleMiddle AgedMitral ValveMitral Valve InsufficiencyProspective StudiesRegistriesStroke VolumeTreatment OutcomeVentricular Function, Leftresearch article31732437open access10.1016/j.rec.2019.07.0181885-5857https://digibuo.uniovi.es/dspace/bitstream/10651/53836/1/Transcatheter%20mitral.pdf